StreetInsider.com News Articles

Form 3 Pyxis Oncology, Inc. For: Jun 30 Filed by: Gordon Craig D

Fri, 10 Jul 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260710/26757435.html

Form 3 Pyxis Oncology, Inc. For: Jun 30 Filed by: Gordon Craig D

Fri, 10 Jul 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260710/26757435.html

Form SCHEDULE 13G Pyxis Oncology, Inc. Filed by: BIOTECHNOLOGY VALUE FUND L P

Fri, 10 Jul 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260710/26757410.html

Form SCHEDULE 13G Pyxis Oncology, Inc. Filed by: BIOTECHNOLOGY VALUE FUND L P

Fri, 10 Jul 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260710/26757410.html

H.C. Wainwright Reiterates Buy Rating on Pyxis Oncology Inc. (PYXS)

Mon, 06 Jul 2026 06:34:49 -0400

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating and $7.00 price target on Pyxis Oncology Inc. (NASDAQ: PYXS).

The analyst commented: "Pyxis provided an update on clinical data timeline concurrent with an announcement regarding a fund raise on June 30. Management now expects updated data from the ongoing Phase 1 study with monotherapy MICVO in 2L+ R/M head and neck squamous cell carcinoma (HNSCC) in Fall 2026 versus prior guidance of mid-2026 and the update Phase 1/2 study evaluating the combination of MICVO and KEYTRUDA in 1L/2L+ settings in 4Q26 versus prior 2H26 guidance. The monotherapy data update is expected

Form 4 Pyxis Oncology, Inc. For: Jun 30 Filed by: Dupont Jakob

Thu, 02 Jul 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260702/26728454.html

Form 4 Pyxis Oncology, Inc. For: Jun 30 Filed by: Dupont Jakob

Thu, 02 Jul 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260702/26728454.html

Form 8-K Pyxis Oncology, Inc. For: Jun 30

Thu, 02 Jul 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260702/26728160.html

Form 8-K Pyxis Oncology, Inc. For: Jun 30

Thu, 02 Jul 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260702/26728160.html

Form SCHEDULE 13G/A Pyxis Oncology, Inc. Filed by: GordonMD Global Investments LP

Thu, 02 Jul 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260702/26727804.html

Form SCHEDULE 13G/A Pyxis Oncology, Inc. Filed by: GordonMD Global Investments LP

Thu, 02 Jul 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260702/26727804.html

Pyxis Oncology Inc. (PYXS) PT Lowered to $7 at Leerink

Thu, 02 Jul 2026 05:05:50 -0400

Leerink analyst Jeffrey La Rosa lowered the price target on Pyxis Oncology Inc. (NASDAQ: PYXS) to $7.00 (from $9.00) while maintaining a Outperform rating.

The analyst comments "Bottom Line: We reiterate our positive view of Pyxis (PYXS, OP) and their lead EDB-FN-targeted ADC, micvotabart pelidotin (micvo), supported by the decision of several prominent investors to provide private financing ahead of a more fulsome Ph 1 dose expansion update in the fall. We maintain our constructive view that micvo offers a differentiated value proposition as a broadly acting agent in 2L+ SCCHN with therapeutic utility across pertinent patient segments (e.g., HPV +

Pyxis Oncology Inc. (PYXS) PT Lowered to $7 at Leerink

Thu, 02 Jul 2026 05:05:50 -0400

Leerink analyst Jeffrey La Rosa lowered the price target on Pyxis Oncology Inc. (NASDAQ: PYXS) to $7.00 (from $9.00) while maintaining a Outperform rating.

Form 144 Pyxis Oncology, Inc. Filed by: Dupont Jakob

Tue, 30 Jun 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260630/26713738.html

Form 144 Pyxis Oncology, Inc. Filed by: Dupont Jakob

Tue, 30 Jun 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260630/26713738.html

Pyxis Oncology raises up to $114M in private placement for MICVO

Tue, 30 Jun 2026 07:30:18 -0400

Pyxis Oncology, Inc. (Nasdaq: PYXS) has entered into definitive securities purchase agreements for a private placement expected to generate approximately $50 million in gross proceeds, with an additional approximately $64 million possible if accompanying warrants are exercised in full for cash.

The financing was led by BVF Partners L.P., with participation from GordonMD Global Investments, RTW Investments, and Coastlands Capital. Wells Fargo Securities acted as sole placement agent.

Under the terms of the transaction, Pyxis Oncology agreed to sell 19,600,153 shares of common stock at $2.551 per share, along with warrants to purchase an equal number of shares at an exercise price

Pyxis Oncology Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key Clinical Milestones

Tue, 30 Jun 2026 07:30:00 -0400

Expected to extend cash runway into the second quarter of 2027, supporting additional follow-up for 2L+ R/M HNSCC patients treated with MICVO at or below a dose cap

Company now expects updated Phase 1 monotherapy data in Fall 2026 and updated Phase 1/2 combination data in the fourth quarter of 2026

Financing led by BVF Partners L.P. with participation from GordonMD Global Investments, RTW Investments, and Coastlands Capital

BOSTON, June 30, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that

Pyxis Oncology Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key Clinical Milestones

Tue, 30 Jun 2026 07:30:00 -0400

Expected to extend cash runway into the second quarter of 2027, supporting additional follow-up for 2L+ R/M HNSCC patients treated with MICVO at or below a dose cap

Company now expects updated Phase 1 monotherapy data in Fall 2026 and updated Phase 1/2 combination data in the fourth quarter of 2026

Financing led by BVF Partners L.P. with participation from GordonMD Global Investments, RTW Investments, and Coastlands Capital

BOSTON, June 30, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that

Form 8-K Pyxis Oncology, Inc. For: Jun 15

Mon, 15 Jun 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260615/26647720.html

Form 8-K Pyxis Oncology, Inc. For: Jun 15

Mon, 15 Jun 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260615/26647720.html

Form 10-Q Pyxis Oncology, Inc. For: Mar 31

Thu, 14 May 2026 07:56:00 -0400

si-local-file:///var/storage/secattach/20260514/26490117.html

Form 10-Q Pyxis Oncology, Inc. For: Mar 31

Thu, 14 May 2026 07:56:00 -0400

si-local-file:///var/storage/secattach/20260514/26490117.html

Pyxis Oncology, Inc. (PYXS) Reports In-Line Q1 EPS

Thu, 14 May 2026 07:53:21 -0400

Pyxis Oncology, Inc. (NASDAQ: PYXS) reported Q1 EPS of ($0.37), in-line with the analyst estimate of ($0.37).

For earnings history and earnings-related data on Pyxis Oncology, Inc. (PYXS) click here.

Form 8-K Pyxis Oncology, Inc. For: May 14

Thu, 14 May 2026 07:37:00 -0400

si-local-file:///var/storage/secattach/20260514/26490018.html

Form 8-K Pyxis Oncology, Inc. For: May 14

Thu, 14 May 2026 07:37:00 -0400

si-local-file:///var/storage/secattach/20260514/26490018.html